AstraZeneca topped off a very busy week with the company’s first-quarter 2022 financial report, citing a total of $11.39 billion in revenue, a whopping increase of 60 percent. That performance was driven by the acquisition of Alexion and several contracts for Vaxzevria, AstraZeneca’s COVID-19 vaccine developed with the University of Oxford.

AstraZeneca’s Alexion received a supplemental New Drug Application approval for Ultomiris (ravulizumab-cwvz) from the U.S. Food and Drug Administration to treat adults with generalized myasthenia gravis (gMG).

AstraZeneca’s rare disease arm Alexion agreed to resolve all patent disputes with Chugai Pharmaceutical regarding the prescription drug Ultomiris (ravulizumab) by signing a settlement agreement that will involve a one-time payment of $775 million.